Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1K23HL177311-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Abbott | INDUSTRY |
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
The CardioClip study is exploring the use of a wireless sensor to monitor pressure in the pulmonary artery. This sensor is inserted much like the mTEER procedure, a non-surgical method through a vein in the groin. The investigators want to find out if the sensor, by constantly sending information about heart function, can help improve patient outcomes. This means doctors could adjust medications based on real-time pressure changes detected by the sensor. The results from this study will help pave the way for future trials, asking if using these wireless sensors could benefit people with valve disease and heart failure.
Patients with heart failure suffer considerably. They experience an increased risk of death and are hospitalized with symptoms of heart failure frequently. Often times, heart failure results in abnormal function of the mitral valve (one of the key valves separating the heart's main pumping chamber - the left ventricle - from the left atrium, which collects oxygenated blood from arteries in the lung). This abnormal function causes the valve to leak - a condition called mitral regurgitation - that perpetuates and can exacerbate heart failure.
Recently, researchers have developed a procedure for patients with mitral regurgitation in the setting of heart failure called mitral transcatheter edge-to-edge repair (mTEER). In this procedure, a "clip" is deployed to grasp the mitral valve leaflet and re-approximate them, thereby reducing the amount of mitral regurgitation. This procedure is performed by accessing one of the large veins in the body and no surgical intervention is required. Patients typically recover within 24 hours and are discharged home without the prolonged recovery periods associated with traditional therapies for mitral regurgitation like open heart surgery and mitral valve repair or replacement. Moreover, the procedure is exceedingly safe, with a very low risk of significant adverse complications.
While mTEER reduces the risk of death and hospitalization for heart failure compared with the standard of care (i.e., medicines geared at improving heart function), many patients still suffer significant adverse events within a five year period. Accordingly, the investigators are interested in identifying strategies to further improve outcomes for patients with heart failure and significant mitral regurgitation. The CardioClip study endeavors to use another technology - a wireless pulmonary artery pressure sensor - that is implanted in a similar fashion to the way mTEER is performed (i.e., percutaneously, without surgery, through one of the veins in the groin), to see whether clinical outcomes can be improved further. The sensor continuously transmits information regarding heart function to clinicians who can optimize medications and their doses according to dynamic changes in pressure noted by the sensor.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CardioMems | Experimental | Participants randomized to this arm will receive hemodynamic-guided GDMT titration with CardioMems. |
|
| Usual Care | No Intervention | Participants randomized to this arm will receive usual care involving GDMT. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CardioMEMS | Device | Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary (OS) score between baseline (pre-mTEER) and 12 months after mTEER. | The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL) within a 2-week recall period. To facilitate interpretation, all scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life (i.e., higher score indicates a better outcome). The Overall Summary (OS) score is the mean of four subdomain scores, each ranging from 0 to 100. A higher OS score indicates better outcome. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| All-cause mortality rate at 12 months | All-cause mortality rate will be calculated at 12 months. | 12 months |
| Rate of HFH at 12 months | Heart failure hospitalization (HFH) rate will be calculated. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kate Dalton, MS, RD, CCRC | Contact | (347) 514-3366 | keb2114@cumc.columbia.edu |
| Name | Affiliation | Role |
|---|---|---|
| Nir Uriel, MD | Columbia University | Principal Investigator |
| Michael Brener, MD | Columbia University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Columbia University Irving Medical Center / NewYork-Presbyterian Hospital | Recruiting | New York | New York | 10032 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008944 | Mitral Valve Insufficiency |
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Evaluating the effect of hemodynamic-guided GDMT titration with CardioMems on HFH in individuals with functional MR and HF undergoing mTEER, compared to usual care involving GDMT.
Not provided
Not provided
Not provided
| 12 months |
| Number of participants who achieve excellent clinical outcome | An excellent clinical outcome is defined by a) survival, b) KCCQ-OS >60 points, and c) no decline ≥10 points in the KCCQ-OS relative to baseline at 12 months | 12 months |
| KCCQ score - Physical Function domain | The KCCQ-OS evaluates health status from four principal domains: physical function, social function, symptoms, and quality of life. Participants receive a score for 0 to 100 in each domain, with higher scores indicating better health status in that specific domain. The score for each domain will be an individual secondary endpoint. | Baseline, 1 month, 6 months, 12 months post-mTEER |
| KCCQ score - Social Function domain | The KCCQ-OS evaluates health status from four principal domains: physical function, social function, symptoms, and quality of life. Participants receive a score for 0 to 100 in each domain, with higher scores indicating better health status in that specific domain. The score for each domain will be an individual secondary endpoint. | Baseline, 1 month, 6 months, 12 months post-mTEER |
| KCCQ score - Symptoms domain | The KCCQ-OS evaluates health status from four principal domains: physical function, social function, symptoms, and quality of life. Participants receive a score for 0 to 100 in each domain, with higher scores indicating better health status in that specific domain. The score for each domain will be an individual secondary endpoint. | Baseline, 1 month, 6 months, 12 months post-mTEER |
| KCCQ score - Quality of Life domain | The KCCQ-OS evaluates health status from four principal domains: physical function, social function, symptoms, and quality of life. Participants receive a score for 0 to 100 in each domain, with higher scores indicating better health status in that specific domain. The score for each domain will be an individual secondary endpoint. | Baseline, 1 month, 6 months, 12 months post-mTEER |
| Change in New York Heart Association (NYHA) Classification at 1-, 6-, and 12-months post-mTEER relative to baseline. | The different classes in the NYHA Classification of Heart Failure are: Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort. | Baseline, 1 month, 6 months, 12 months |
| 6-minute walk test (6MWT) at 12 months | The 6 minute walk test (6MWT) assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance. The score of the test is the distance a patient walks in 6 minutes at 12 months. | 12 months |
| Change in 6-minute walk test (6MWT) from baseline to 12 months | The 6 minute walk test (6MWT) assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance. The score of the test is the distance a patient walks in 6 minutes. Change of score at baseline and then at 12 months will be calculated. | Baseline and 12 months |
| Win ratio | Win ratio for the hierarchical endpoint of KCCQ improvement ≥10 points at 12 months, NYHA functional class improvement ≥1 class at 12 months, 6MWT improvement ≥30 meters at 12 months, HFH at 12 months, and all-cause mortality at 12 months. | Baseline and 12 months |
| Echocardiographic estimates of RV-PA coupling indices | Right ventricular (RV)-pulmonary arterial (PA) (RV-PA) coupling indices will be measured (mm/mmHg) will be measured to determine how the right ventricle and pulmonary circulation interact. | 12 months |
| Device-related (MitraClip) complications at 12 (single-leaflet device detachment, device embolization, endocarditis requiring surgery, mitral stenosis requiring surgery) | MitraClip complications | 12 months |
| Single-leaflet Device Detachments | Device-related MitraClip complications: Total number of single-leaflet device detachment events. | 12 months |
| Device Embolizations (MitraClip) | Device-related MitraClip complications: Total number of device embolizations. | 12 months |
| Endocarditis (Requiring Surgery) | Device-related MitraClip complications: Total number of endocarditis events requiring surgery. | 12 months |
| Mitral Stenosis (Requiring Surgery) | Device-related MitraClip complications: Total number of mitral stenosis events requiring surgery. | 12 months |
| Device- or System-related Failures | Device-related CardioMEMS complications: Total number of device- or system-related failures. | 12 months |
| In Situ Pulmonary Thrombosis | Device-related CardioMEMS complications: Total number of in situ pulmonary thrombosis. | 12 months |
| Device Embolizations (CardioMEMS) | Device-related CardioMEMS complications: Total number of device embolizations | 12 months |